™ 100 mg/ml Oral Solution
A clear, dense, brownish-yellow solution containing 100 mg doxycycline, as doxycycline hyclate, per ml.
In chickens, prevention and treatment of chronic respiratory disease (CRD) and mycoplasmosis caused by microorganisms sensitive to doxycycline. In pigs, prevention of clinical respiratory disease due to Pasteurella multocida
and Mycoplasma hyopneumoniae
sensitive to doxycycline. The presence of the disease in the herd should be established before treatment.
Instructions for use
Karidox is to be administered in drinking water. For chickens, give 10 - 20 mg of doxycycline / kg liveweight / day for 3-5 days (i.e. 0.5-1.0 ml of product / litre of drinking water / day). For pigs, give 10 mg of doxycycline / kg b.w. / day for 5 days (i.e. 1 ml of product / 10 kg b.w. / day). To ensure the correct dosage and avoid underdosing, liveweight should be determined as accurately as possible. The consumption of medicated water depends on the clinical condition of the animals. In order to achieve the correct dosage, the concentration of doxycycline has to be adjusted accordingly. Use appropriate and properly calibrated dosing equipment. Medicated water should be the only water available. The medicated water may be used only for 24 hours and should be made up freshly every day. Unconsumed medicated water should be disposed of in accordance with local requirements. If no improvement in clinical signs is seen within the recommended duration of treatment, the diagnosis should be reviewed and the treatment changed.
Do not use Karidox in animals hypersensitive to tetracyclines, in animals with hepatic dysfunction or for
Allergic and photosensitivity reactions can occur. Intestinal flora may be affected if treatment is very
prolonged, and this may result in digestive disturbance.
Do not administer Karidox to laying birds from four weeks before the start of lay and during lay. It
should not be used during pregnancy or lactation.
Absorption of doxycycline may be reduced by high concentrations of calcium, iron, magnesium or
aluminium in the diet. Do not administer with antacids, kaolin or iron preparations. Do not administer
together with bactericidal antibiotics. The solubility of the product depends on acidity and will it
precipitate if mixed in an alkaline solution. Do not administer with milk replacers. Special precautions for use in animals
Avoid administration in oxidized drinking equipment.
Resistance against doxycycline may vary, so the use of this product should be based on culture and
sensitivity of micro-organisms from diseased cases on the farm or on recent experience on the farm.
Inappropriate use of the product may increase the prevalence of bacteria resistant to doxycycline and may
decrease the effectiveness of treatment with tetracyclines, owing to the potential for cross-resistance. Special precautions to be taken by the person administering Karidox to animals
Do not handle the
product if you are hypersensitive to tetracyclines. Wear gloves, overalls and approved safety glasses.
This product is acid and likely to be irritant. Avoid its contact with the skin and eyes. In case of contact
with skin, rinse immediately with plenty of water. In case of contact with eyes, rinse immediately with
copious amounts of water and seek medical advice. Do not smoke, eat or drink while handling this
product. Administer the product with caution. The product can be harmful by skin contact and inhalation
and may cause eye irritation. In case of accidental ingestion seek medical advise and show the label to
the doctor. If any clinical sign should appear, such as a cutaneous eruption, seek prompt medical advice.
Swelling of the face, lips or eyes or respiratory difficulties are the most serious signs which require urgent
DATA SHEET: Karidox™ 100 mg/ml Oral Solution
Doxycycline is a bacteriostatic agent that acts by interfering with the bacterial protein syntesis of sensitive species. It is a semi-synthetic tetracycline derived from oxytetracycline. It acts on the subunit 30S of the bacterial ribosome, to which it is linked reversibly, blocking the union between aminoacyl-tRNA (transfer RNA) and the mRNA-ribosome complex, preventing the addition of new aminoacids to the growing peptide chain and thus interfering with protein synthesis. Doxycycline is active against Gram-positive and Gram-negative bacteria. Spectrum of activity:
sensitivity of Pasteurella multocida
and Bordetella bronchiseptica
strains isolated from pigs to doxycycline has been determined by a plate-diffusion method, and against Mycoplasma hyopneumoniae
by a dilution method. The MIC90 values are 0.517 mcg/ml, 0.053 mcg/ml and 0.200 mcg/ml, respectively. According to the NCCLS standard, strains sensitive to doxycycline have MIC values below or equal to 4 mcg/ml and those resistant have MIC values above or equal to 16 mcg/ml. Feeding can modify the oral bioavailability of doxycycline. After fasting, the bioavailability is 10-15% greater than in fed animals. Doxycycline is well distributed through the body, as it is highly lipid soluble. It accumulates in liver, kidney, bones and the intestine; enterohepatic recycling occurs. In the lungs, it always reaches higher concentrations than in plasma. Therapeutic concentrations have been detected in aqueous humour, myocardium, reproductive tissues, brain and mammary gland. Plasma-protein binding is 90-92%. 40% of the drug is metabolized and largely excreted through faeces (biliary and intestinal route), mainly as microbiologically inactive conjugates.
Do not mix Karidox with other veterinary medicinal products. The shelf-life of medicated water is 24 hours.
The shelf-life after opening the primary packaging is 28 days. Do not store Karidox at temperatures above 25°C. Protect it from light.
Polyethylene bottles containining 1 litre.
Poligono Industrial La Borda Mas Pujades, 11-12 08140 – Caldes de Montbui Barcelona Spain
Nimrod Veterinary Products Ltd 42 A P Ellis Road Rissington Business Park Upper Rissington Gloucestershire GL54 2QB Telephone: 01451 812243 e-mail: [email protected]
Clinical Psychology Review 26 (2006) 17 – 31The empirical status of cognitive-behavioral therapy:Andrew C. Butler a,*, Jason E. Chapman b, Evan M. Forman c, Aaron T. Beck aa University of Pennsylvania and the Beck Institute for Cognitive Therapy and Research, United Statesb Medical University of South Carolina, United StatesReceived 20 September 2004; received in revised form 7 June 2
É contagioso Minha amiga Patsy estava me contando uma história. "Aí eu estava no teatro", ela começou, "e dobrei meu casaco com todo o cuidado no encosto da cadeira, mas então chegou um sujeito." E nesse momento eu a interrompi, porque esse negócio de casaco sempre me intrigou. Quando estou num teatro, dobro meu casaco no colo ou jogo no braço da cadeira, mas Patsy sempre es